Results 141 to 150 of about 54,012 (256)

Diagnosis and treatment of neurofibromatosis type 1 with malignant transformation and multiple gastrointestinal stromal tumors: a case report and literature review. [PDF]

Front Med (Lausanne)
Wang H, Liu J, Huang B, Lai Z, Fang Y, Fu G.   +5 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

A CT-based radiomics model for preoperative risk stratification of gastrointestinal stromal tumors. [PDF]

Front Oncol
Wan T, Song Y, Wang X, Huang P, Wang Z, Fan B, Dong W.   +6 more
europepmc   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Impact of Imatinib Intake Timing on Oncological Outcomes in Metastatic Gastrointestinal Stromal Tumors (GISTs): A Retrospective Single-Institute Study. [PDF]

Cureus
Bahida K, El Fadli M, Zouiten O, Afani L, Belbaraka R.   +4 more
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial. [PDF]

Nat Med
Merriam P, Morrow JJ, Mazzola E, Solimini NL, Gokhale PC, Chi P, Chen AP, Agulnik M, Burgess M, Schuetze SM, Somaiah N, Van Tine BA, Pollack SM, Tinoco G, Trent J, Wilky BA, Bothwick N, Eschle BK, Nguyen V, Beumer JH, Rastkari N, Jiwani S, Wu PI, Pelosof L, Hemming ML, Shapiro GI, Demetri G, Bernstein B, George S.   +28 more
europepmc   +1 more source

Spatial Transcriptomics and Bulk RNA‐Seq Analysis Revealed Molecular Classification of Invasive Lobular Carcinoma

Cancer Science, EarlyView.
Spatial transcriptomics and bulk RNA‐seq data analysis revealed the molecular characteristics of invasive lobular carcinoma (ILC). ILC was classified into three clusters: proliferative, immunoreactive, and stromal‐rich, with different prognoses. ABSTRACT Invasive lobular carcinoma (ILC) is a special type of breast cancer.
Momoko Tokura, Jun Nakayama, Hironori Suzuki, Mieko Ochi, Miyaka Umemori, Sho Shiino, Masayuki Yoshida, Shin Takayama, Yasushi Yatabe, Yusuke Yamamoto   +9 more
wiley   +1 more source

Clinical Features and Factors Contributing to Preoperative Misdiagnosis of Gastric Gastrointestinal Stromal Tumors: A Retrospective Analysis of 27 Cases. [PDF]

Gastroenterol Res Pract
Xie J, Yang J, Yan Z.
europepmc   +1 more source

Organ‐Specific Cancer‐Associated Fibroblast Subtypes Across the Digestive System Linked to Cancer Hallmarks

Cancer Science, EarlyView.
We integrated 14 single‐cell RNA‐seq datasets and 18 bulk cohorts to define eight CAF subtypes in GI cancers. myCAF1 and myCAF2 promoted immunosuppressive, poor‐prognosis niches, whereas iCAF1 was linked to favorable prognosis and antitumor immunity.
Huaitao Wang, Takashi Semba, Atsuko Yonemura, Hiroshi Naito, Lingfeng Fu, Takuya Tajiri, Masaaki Iwatsuki, Takatsugu Ishimoto   +7 more
wiley   +1 more source